Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIELD trial of CL2020 in neonatal hypoxic ischemic encephalopathy
jRCT2043190112Active, not recruiting
- Sponsor
- Life Science Institute
- Start
- Mar 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of CL2020 in hypoxic-ischemic encephalopathy (HIE) (2 cohorts), sponsored by Life Science Institute. Primary endpoint: Incidence of adverse events until 12 weeks. Started Mar 2020; status: active, not recruiting.
02
Drugs
CL2020
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on jRCT2043190112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2043190112.